checkAd

    FMC ALERT  121  2 Kommentare Bragar Eagel & Squire, P.C. is Investigating FMC Corporation on Behalf of FMC Stockholders and Encourages Investors to Contact the Firm

    Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against FMC Corporation (“FMC” or the “Company”) (NYSE: FMC) on behalf of FMC stockholders. Our investigation concerns whether FMC has violated the federal securities laws and/or engaged in other unlawful business practices.

    Click here to participate in the action.

    On July 10, 2023, before the market opened, FMC Corporation, despite raising its full-year revenue guidance in May 2023, announced that it was cutting its revenue for the second quarter and the 2023 fiscal year. It announced that “the revised guidance is driven by substantially lower-than-expected volumes due to an abrupt and significant reduction in inventory by channel partners, which only became evident towards the end of May and continued through the remainder of the quarter[.]”

    On this news, the price of FMC stock fell by $11.62 per share, or 11.14%, to close at $92.63 on July 10, 2023.

    If you purchased or otherwise acquired FMC shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

    About Bragar Eagel & Squire, P.C.:

    Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.


    The FMC Stock at the time of publication of the news with a raise of +0,06 % to 95,63EUR on NYSE stock exchange (20. Juli 2023, 02:04 Uhr).


    Business Wire (engl.)
    0 Follower
    Autor folgen

    FMC ALERT Bragar Eagel & Squire, P.C. is Investigating FMC Corporation on Behalf of FMC Stockholders and Encourages Investors to Contact the Firm Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against FMC Corporation (“FMC” or the “Company”) (NYSE: FMC) on behalf of FMC stockholders. Our investigation concerns whether FMC …

    Schreibe Deinen Kommentar

    Kommentare

    Avatar
    07.09.23 20:44:49
    Bild: 1213_20230907204208_FMCCorp

    7.9.
    Blue Orca Hits Fertilizer-Focused FMC With Short Report - What's Going On?
    https://www.benzinga.com/news/23/09/34322722/blue-orca-hits-…
    ...
    Blue Orca Capital is short on FMC Corporation noting that the company has not disclosed its recent legal setbacks worldwide. The report says, "The dam has broken."

    This situation has arisen at a particularly unfavorable moment for FMC, as its revenues have already been severely impacted by a global oversupply of inventory.

    FMC recently reported a 30% Y/Y decline in revenue, and this is before generic competition is expected to intensify in key markets, setting the stage for a challenging second half of 2023, with the potential for a significant downturn rather than a recovery, the report adds.

    The short report adds that FMC has misled investors by suggesting that it would not encounter generic competition for its flagship diamides.

    In reality, due to recent adverse legal rulings, generic alternatives have already entered important markets in India and China and are poised to do so in Brazil.

    Blue Orca says an investigation has identified numerous legal competitors, including industry giants, actively producing and selling generic variants of FMC's top-selling insecticide in FMC's most critical markets, often at substantially reduced prices.

    For example, in China, these competitors offer generics up to 80% lower than FMC's branded equivalent.

    In India, the Delhi High Court recently found FMC guilty of deceptive practices before the court and the patent office, leading well-funded rivals to introduce generic versions of FMC's leading CTPR product at discounted rates.

    These competitors are projected to capture 40-50% of FMC's CTPR diamide market share in India within the next year.

    ...
    Avatar
    07.09.23 20:41:49
    FMC Corp

    Disclaimer